Shares of Verona Pharma plc (NASDAQ:VRNA – Get Rating) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the […]
Verona Pharma (NASDAQ:VRNA – Get Rating) had its price objective raised by analysts at Truist Financial from $28.00 to $32.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Truist Financial’s target price points to a potential upside of 51.66% from the stock’s previous close. VRNA has been the topic […]
Shares of Verona Pharma plc (NASDAQ:VRNA – Get Rating) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock […]
Operator: Good morning. Welcome to Verona Pharma s First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode.
Verona Pharma plc (NASDAQ:VRNA – Get Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,290,000 shares, a growth of 21.8% from the April 15th total of 1,880,000 shares. Based on an average daily volume of 558,400 shares, the short-interest ratio is […]